Short Interest in Xenetic Biosciences, Inc. (NASDAQ:XBIO) Increases By 231.4%

Xenetic Biosciences, Inc. (NASDAQ:XBIO) was the recipient of a large increase in short interest in the month of January. As of January 30th, there was short interest totaling 16,141 shares, an increase of 231.4% from the January 15th total of 4,870 shares. Approximately 0.8% of the shares of the company are sold short. Based on an average trading volume of 34,180 shares, the days-to-cover ratio is currently 0.5 days. Based on an average trading volume of 34,180 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.8% of the shares of the company are sold short.

Xenetic Biosciences Stock Performance

NASDAQ XBIO opened at $2.13 on Wednesday. The company has a market cap of $4.88 million, a price-to-earnings ratio of -1.04 and a beta of 2.29. The company has a 50 day moving average of $2.28 and a 200-day moving average of $2.95. Xenetic Biosciences has a 1-year low of $1.90 and a 1-year high of $13.93.

Xenetic Biosciences (NASDAQ:XBIO) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.16. The firm had revenue of $1.03 million for the quarter. Xenetic Biosciences had a negative return on equity of 64.66% and a negative net margin of 110.42%. On average, equities research analysts forecast that Xenetic Biosciences will post -1.01 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenetic Biosciences in a research report on Wednesday, January 21st. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Reduce”.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.